These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12570696)

  • 21. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.
    Guihot A; Tubiana R; Breton G; Marcelin AG; Samri A; Assoumou L; Goncalves E; Bricaire F; Costagliola D; Calvez V; Rouzioux C; Autran B; Katlama C; Carcelain G; ;
    AIDS; 2010 Feb; 24(4):614-7. PubMed ID: 19952710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration.
    Russell RR; Bowmer MI; Nguyen C; Grant MD
    Viral Immunol; 2001; 14(4):379-89. PubMed ID: 11792067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
    Spritzler J; Mildvan D; Russo A; Asthana D; Livnat D; Schock B; Kagan J; Landay A; Haas DW;
    Clin Infect Dis; 2003 Aug; 37(4):551-8. PubMed ID: 12905140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
    Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
    Negredo E; Massanella M; Puig J; Pérez-Alvarez N; Gallego-Escuredo JM; Villarroya J; Villarroya F; Moltó J; Santos JR; Clotet B; Blanco J
    Clin Infect Dis; 2010 May; 50(9):1300-8. PubMed ID: 20367229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of total lymphocyte count for monitoring response to antiretroviral therapy.
    Schreibman T; Friedland G
    Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of the immune system with antiretroviral therapy: the end of opportunism?
    Powderly WG; Landay A; Lederman MM
    JAMA; 1998 Jul; 280(1):72-7. PubMed ID: 9660367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
    Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS
    Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases.
    Schnittman SM; Fox L
    AIDS Res Hum Retroviruses; 1997 Jul; 13(10):815-8. PubMed ID: 9197375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
    Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
    AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.